Diagnostic Pharmaceutical Development Company NanoScan Imaging (“NSI”) was formed to continue the clinical development of N1177, a novel iodinated nanoparticulate CT contrast agent targeting the nearly $6 billion radiopharmaceutical market.
Customer Reviews for NANOSCANIMAGING
Be the first to review NANOSCANIMAGING - Use the thumbs to get started!
Click to Rate: 0 thumbs up, 0 thumbs down
NANOSCANIMAGING has not yet completed their interview.
Contact NANOSCANIMAGING:
